TY  - JOUR
AU  - Quintanal-Villalonga, Álvaro
AU  - Ferrer, Irene
AU  - Guruceaga, Elizabeth
AU  - Cirauqui, Cristina
AU  - Marrugal, Ángela
AU  - Ojeda, Laura
AU  - García, Santiago
AU  - Zugazagoitia, Jon
AU  - Muñoz-Galván, Sandra
AU  - Lopez-Rios, Fernando
AU  - Montuenga, Luis
AU  - Vicent, Silvestre
AU  - Molina-Pinelo, Sonia
AU  - Carnero, Amancio
AU  - Paz-Ares, Luis
PY  - 2020
DO  - 10.1016/j.ebiom.2020.102683
UR  - http://hdl.handle.net/10668/15186
T2  - EBioMedicine
AB  - Fibroblast growth factor receptor (FGFR)1 and FGFR4 have been associated with tumorigenesis in a variety of tumour types. As a therapeutic approach, their inhibition has been attempted in different types of malignancies, including lung cancer, and was...
LA  - en
KW  - FGFR inhibitors
KW  - FGFR1
KW  - FGFR4
KW  - N-cadherin
KW  - Predictive biomarker
KW  - Animals
KW  - Antineoplastic Agents
KW  - Benzamides
KW  - Biomarkers, Tumor
KW  - Cadherins
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Cell Line, Tumor
KW  - Drug Resistance, Neoplasm
KW  - Female
KW  - Humans
KW  - Lung Neoplasms
KW  - Mice
KW  - Mice, Nude
KW  - Piperazines
KW  - Pyrazoles
KW  - Receptor, Fibroblast Growth Factor, Type 1
KW  - Receptor, Fibroblast Growth Factor, Type 4
KW  - Tumor Cells, Cultured
TI  - FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy.
TY  - research article
VL  - 53
ER  -